Form 8-K - Current report:
SEC Accession No. 0001213900-17-004429
Filing Date
2017-05-01
Accepted
2017-05-01 12:20:50
Documents
3
Period of Report
2017-05-01
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT f8k050117_dandritbiotech.htm 8-K 31523
2 FORM OF SUBSCRIPTION AGREEMENT f8k050117ex10i_dandritbio.htm EX-10.1 216719
3 FORM OF WARRANT f8k050117ex10ii_dandritbio.htm EX-10.2 57506
  Complete submission text file 0001213900-17-004429.txt   307064
Mailing Address DANDRIT BIOTECH A/S FRUEBJERGVEJ 3 BOX 62 2100 COPENHAGEN G7
Business Address DANDRIT BIOTECH A/S FRUEBJERGVEJ 3 BOX 62 2100 COPENHAGEN G7 45 39179840
DanDrit Biotech USA, Inc. (Filer) CIK: 0001527728 (see all company filings)

EIN.: 452259340 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 000-54478 | Film No.: 17799443
SIC: 2834 Pharmaceutical Preparations